trending Market Intelligence /marketintelligence/en/news-insights/trending/yum7frvasss_nbyuzscmnw2 content esgSubNav
In This List

ASCO conference: Adaptimmune T-cell therapy shrinks tumors in pilot study

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: Adaptimmune T-cell therapy shrinks tumors in pilot study

Adaptimmune Therapeutics PLC said its cancer treatment using NY-ESO spear T-cells shrank a type of soft tissue cancer in an ongoing pilot study.

The clinical program, which treated eight patients with myxoid/round cell liposarcoma — a cancer that arises in fat cells — is being transitioned to GlaxoSmithKline PLC.

Of the eight patients dosed, a reduction in tumor size was observed in four, one of which is unconfirmed. Three patients had stable disease, meaning the tumor neither shrank nor grew, while one patient is awaiting assessment.

Additionally, the NY-ESO spear T-cells were generally well-tolerated by the patients. Most of the adverse effects seen were consistent with those seen in patients being treated with cancer immunotherapies.

U.K.-based Adaptimmune said the trial is open and actively enrolling patients with liposarcoma. In addition to the initial 10 patients expected to participate, five more patients could potentially join.

There are about 2,000 patients in the U.S. and Europe with myxoid/round cell liposarcoma each year, the company said.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on site and an additional 3,350 abstracts to be published online.